<SEC-DOCUMENT>0001615774-17-003470.txt : 20170703
<SEC-HEADER>0001615774-17-003470.hdr.sgml : 20170703
<ACCEPTANCE-DATETIME>20170703142443
ACCESSION NUMBER:		0001615774-17-003470
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170703
DATE AS OF CHANGE:		20170703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-216031
		FILM NUMBER:		17945190

	BUSINESS ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>s106726_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 75%; font-size: 10pt"><B>Prospectus Supplement </B></TD>
    <TD NOWRAP STYLE="width: 25%; font-size: 10pt">&nbsp;<B>Filed Pursuant to Rule 424(b)(3)</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="font-size: 10pt"><B>To Prospectus dated&nbsp;March 31, 2017</B></TD>
    <TD NOWRAP STYLE="font-size: 10pt"><B>&nbsp;Registration Statement No. 333-216031</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>PROSPECTUS SUPPLEMENT</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>664,000 Class A Units Consisting
of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>Common Stock and Warrants and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>3,502 Class B Units Consisting
of Series A Convertible</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>Preferred Stock and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are supplementing the prospectus dated March 31, 2017 covering
the sale of up to 664,000 Class A Units, consisting of Common Stock and Warrants, and 3,502 Class B Units, consisting of Series
A Convertible Preferred Stock and Warrants, to add certain information as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This prospectus supplement supplements information contained in
the prospectus dated March 31, 2017 and should be read in conjunction therewith. This prospectus supplement is not complete without,
and may not be delivered or utilized except in connection with, the prospectus dated March 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Investing in our common stock and warrants involves certain risks.
See &ldquo;Risk Factors&rdquo; beginning on page 5 of the prospectus dated March 31, 2017 for a discussion of these risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus supplement in truthful or
complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WARRANT EXERCISE ARRANGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On June 29, 2017, we offered to modify the
rights (the &ldquo;Temporary Modification&rdquo;) of the holders of the Warrants sold pursuant to the prospectus (the &ldquo;Warrants&rdquo;).
In accordance with Sections 2 and 3 of the Warrants, the Temporary Modification included: (a) lowering the exercise price of the
Warrants to $0.26 per share, (b) setting the applicable &ldquo;VWAP&rdquo; (as defined in the Warrant) price at $0.52 per share,
and (c) allowing for temporary cashless exercise of the Warrants for all holders that accepted the Temporary Modification before
8:00 a.m. Eastern daylight time on June 30, 2017. Holders of Warrants to purchase a total of approximately 3.0 million shares
of Common Stock accepted the offer resulting in the cancellation of those warrants and the issuance of a total of approximately
1.5 million shares of Common Stock (including shares held in abeyance pursuant to the following). The shares of Common Stock are
expected to be delivered on or about June 30, 2017 and are registered under the Securities Act of 1933, as amended. If delivery
of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% &ldquo;Beneficial Ownership
Limitation&rdquo; (as defined in the Warrant) then the shares in excess of such 4.99% will be held by us in abeyance pending further
instruction from the holder. In connection with the Temporary Modification, we agreed to extend the &quot;Lock-up Period&quot;
contained in section 3.16.1 of the underwriting agreement between us and Aegis Capital Corp., dated March 28, 2017, by 45 days
and the Company agreed not to enter into any further amendments to the Warrants during such extended Lock-up Period.&nbsp; The
Company further agreed not to amend or waive the Lock-Up Period without the prior written consent of the holder accepting the
Temporary Modification. As a result of the Temporary Modification and in accordance with the terms of the Warrants, the Warrant
exercise price was lowered to $0.26 per share for all Warrants that were not exercised as part of the Temporary Modification.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this Prospectus Supplement is June
30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
